Autolus Therapeutics plc (AUTL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20M 40M 60M Q2 '18: 443K Q3 '18: 307K Q4 '18: 296K Q1 '19: 2M Q2 '19: 338K Q3 '19: 297K Q4 '19: 309K Q1 '20: 338K Q2 '20: 293K Q1 '21: 269K Q1 '24: 10.1M Q2 '24: 0 Q3 '24: 0 Q4 '24: 29K Q1 '25: 9M Q2 '25: 20.9M Q3 '25: 21.2M Q4 '25: 24.3M Q1 '26: 26.2M Q2 '26: 45.7M Q3 '18 Q2 '19 Q1 '20 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

-18M -9M 0 9M 18M 27M Q1 '24: 10.1M Q2 '24: 0 Q3 '24: 0 Q4 '24: -11.4M Q1 '25: -9M Q2 '25: -3.5M Q3 '25: -7.4M Q4 '25: -1M Q1 '26: 1.6M Q2 '26: 25.2M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q4 '20: -47.3M Q1 '21: -39.9M Q1 '22: -36.2M Q2 '22: -39.1M Q3 '22: -43.5M Q4 '22: -11.7M Q1 '23: -39.1M Q2 '23: -44.4M Q3 '23: -42.9M Q4 '23: -53.3M Q1 '24: -38.8M Q2 '24: -58.9M Q3 '24: -67.9M Q4 '24: -75.9M Q1 '25: -65.2M Q2 '25: -61.2M Q3 '25: -71.6M Q4 '25: -72.5M Q1 '26: -59.5M Q2 '26: -43.8M Q1 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q4 '20: -42.9M Q1 '21: -33.3M Q1 '22: -37.1M Q2 '22: -42.1M Q3 '22: -42.8M Q4 '22: -27M Q1 '23: -39.8M Q2 '23: -45.6M Q3 '23: -45.8M Q4 '23: -77.2M Q1 '24: -52.7M Q2 '24: -58.3M Q3 '24: -82.1M Q4 '24: -27.6M Q1 '25: -70.2M Q2 '25: -47.9M Q3 '25: -79.1M Q4 '25: -90.3M Q1 '26: -71.6M Q2 '26: -39.1M Q1 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 10M 20M 30M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 11.4M Q1 '25: 18M Q2 '25: 24.4M Q3 '25: 28.6M Q4 '25: 25.3M Q1 '26: 24.6M Q2 '26: 20.5M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '20: -24M Q2 '20: -26.9M Q3 '20: -39.1M Q4 '20: -27.7M Q1 '21: -37.3M Q4 '22: -14.6M Q1 '23: -42.4M Q2 '23: -38.1M Q3 '23: -40.2M Q4 '23: -24.8M Q1 '24: -40.5M Q2 '24: -51.1M Q3 '24: -76.7M Q4 '24: -37.9M Q1 '25: -75.6M Q2 '25: -72.8M Q3 '25: -67.9M Q4 '25: -67.3M Q1 '26: -65.3M Q2 '26: -25.1M Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '20: -26.7M Q2 '20: -29.5M Q3 '20: -43.1M Q4 '20: -33.2M Q1 '21: -39.2M Q4 '22: -15.2M Q1 '23: -46M Q2 '23: -42.5M Q3 '23: -41.7M Q4 '23: -26.3M Q1 '24: -41M Q2 '24: -51.9M Q3 '24: -86.3M Q4 '24: -49M Q1 '25: -83.8M Q2 '25: -80.1M Q3 '25: -72.3M Q4 '25: -68.2M Q1 '26: -68M Q2 '26: -26M Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '22: 90.9M Q2 '22: 90.9M Q3 '22: 91.2M Q1 '23: 173.8M Q2 '23: 173.9M Q3 '23: 174M Q1 '24: 222.2M Q2 '24: 266M Q3 '24: 266.1M Q1 '25: 266.1M Q2 '25: 266.1M Q3 '25: 266.1M Q1 '26: 266.1M Q2 '26: 266.2M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q1 '20: -2.79 Q2 '20: -2.76 Q3 '20: -2.87 Q4 '20: -2.77 Q1 '21: -2.70 Q4 '22: -1.57 Q1 '23: -1.39 Q2 '23: -1.19 Q3 '23: -0.98 Q4 '23: -1.20 Q1 '24: -1.21 Q2 '24: -1.17 Q3 '24: -1.22 Q4 '24: -0.86 Q1 '25: -0.88 Q2 '25: -0.84 Q3 '25: -0.83 Q4 '25: -1.08 Q1 '26: -1.09 Q2 '26: -1.06 Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.